跳至主要内容
临床试验/NCT00197808
NCT00197808已完成4 期

Response of United Kingdom (UK) Infants to a Reduced Primary Schedule With Meningococcal C and Pneumococcal Conjugate Vaccines

Public Health England2 个研究点 分布在 1 个国家目标入组 392 人开始时间: 2005年4月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
392
试验地点
2
主要终点
Immunogenicity

研究概览

简要总结

The purpose of the study is to evaluate the immune responses of UK infants after one or two doses of pneumococcal conjugate vaccine or one or two doses of three different types of meningococcal conjugate vaccine given at either two and three or two and four months of age.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
7 Weeks 至 11 Weeks(Child)
性别
All
接受健康志愿者
是

入选标准

  • •Written informed consent obtained from parent or legal guardian of infant
  • •Age 7-11 weeks at first dose

排除标准

  • •Any contraindications to vaccination as specified in the UK Handbook "Immunisation Against Infectious Disease" (Ed 1996)
  • •< 7 weeks or > 11 weeks at first dose

研究组 & 干预措施

Vaccine schedule 2

Experimental

Menjugate vaccine at 2 and 4 months

干预措施: Men C conjugate vaccine (Biological)

vaccine schedule3

Experimental

Neissvacc at 2 and 3 months

干预措施: Men C conjugate (Biological)

vaccine schedule 4

Experimental

Neissvacc at 2 and 4 months

干预措施: Men C Conjugate (Biological)

Vaccine schedule 5

Experimental

Meningitec at 2 and 3 months

干预措施: Men C conjugate (Biological)

Vaccine schedule 6

Experimental

Meningitec at 2 and 4 months

干预措施: Men C conjugate (Biological)

Vaccine schedule 1

Experimental

Menjugate vaccine at 2 and 3 months

干预措施: menjugate (Biological)

结局指标

主要结局

Immunogenicity

时间窗: 3 months after last sample

SBA men C responses

次要结局

未报告次要终点

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验